Resistant Dermatomyositis Improves Quickly, Significantly With Combination Drug

(MedPage Today) -- DENVER -- Treatment-resistant dermatomyositis improved significantly with the investigational TYK2/JAK1 inhibitor brepocitinib, according to a randomized trial. The higher of two doses of brepocitinib improved the total dermatomyositis...
Source
MedPage Today
Opens original article in a new tab



